<?xml version="1.0"?>
<Articles JournalTitle="Journal of Pharmaceutical Care">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Pharmaceutical Care</JournalTitle>
      <Issn>2322-4630</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Delivery of inhaled medication in children: Revisiting Pharmacological and Practical Issues for Better Health Outcome</title>
    <FirstPage>47</FirstPage>
    <LastPage>54</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Prashant</FirstName>
        <LastName>Mishra</LastName>
        <affiliation locale="en_US">Armed Forces Medical College Pune</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>09</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>20</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">For safe and effective therapy of respiratory disorders in children, delivering the medication at the site of disease i.e. directly into the respiratory tract via aerosolized medication is critical. But, the anatomical and physiological differences in the respiratory tract of infants/children and adults make the delivery of aerosolized medication complicated. This review article will give an overview of the delivery of inhaled medication in children and discuss the pharmacological and specific clinically relevant aspects of medication delivery using nebulizers, pressurized metered dose inhalers (MDIs), and dry powder inhalers (DPIs) in children.</abstract>
    <web_url>https://jpc.tums.ac.ir/index.php/jpc/article/view/636</web_url>
  </Article>
</Articles>
althcare resources. The aim is to study utilization of intravenous Iron Sucrose at patient level and hospital level.&#xA0;
Methods: This prospective-observational study was conducted over 6 months. Case-records of 125 indoor patients were reviewed for intravenous (IV) Iron Sucrose prescription and patient details and treatment details for patients were procured.&#xA0;
Results: 125 patient records were divided in (Antenatal care and Non Antenatal care) ANC and Non ANC groups; and their Mean age was 36(S.D &#xB1; 16) years. IV Iron Sucrose was prescribed the most in anemic pregnant patients 41(32.8%) followed by severely debilitated patients on other injectable drugs 37(6%). The Total administered dose was more than the Standard calculated dose in an alarming 84(67.2%) of the patients. Utilisation of IV iron sucrose in Defined Daily Dose per 100 bed days (DDD/100 bed days) was found to be 0.42 in total patients whereas it was 0.59 in ANC and 0.36 in Non ANC groups.&#xA0;Conclusion: This research highlighted that overutilization and administering more than the required dose of IV iron sucrose, could be effectively tackled by calculation of its standard dose by Ganzoni&#x2019;s formula. Studying the monthly trends and comparing utilization of parenteral iron with the help of DDD/100 bed days by hospitals can help in comparing utilization and also assist for budgetary preparedness of hospitals. There is also a dire need to formulate universally accepted guidelines for the use of parenteral iron in general adult population.</abstract>
    <web_url>https://jpc.tums.ac.ir/index.php/jpc/article/view/631</web_url>
  </Article>
</Articles>
